EP3638226A4 - Potenzial von garcinol gegen adipositas - Google Patents

Potenzial von garcinol gegen adipositas Download PDF

Info

Publication number
EP3638226A4
EP3638226A4 EP18817304.1A EP18817304A EP3638226A4 EP 3638226 A4 EP3638226 A4 EP 3638226A4 EP 18817304 A EP18817304 A EP 18817304A EP 3638226 A4 EP3638226 A4 EP 3638226A4
Authority
EP
European Patent Office
Prior art keywords
garcinol
obesity potential
obesity
potential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18817304.1A
Other languages
English (en)
French (fr)
Other versions
EP3638226A1 (de
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Lakshmi MUNDKUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sami Sabinsa Group Ltd
Original Assignee
Sami Chemicals and Extracts Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Chemicals and Extracts Ltd filed Critical Sami Chemicals and Extracts Ltd
Publication of EP3638226A1 publication Critical patent/EP3638226A1/de
Publication of EP3638226A4 publication Critical patent/EP3638226A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP18817304.1A 2017-06-15 2018-06-13 Potenzial von garcinol gegen adipositas Pending EP3638226A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762519949P 2017-06-15 2017-06-15
US201762523611P 2017-06-22 2017-06-22
PCT/US2018/037242 WO2018231923A1 (en) 2017-06-15 2018-06-13 Anti-obesity potential of garcinol

Publications (2)

Publication Number Publication Date
EP3638226A1 EP3638226A1 (de) 2020-04-22
EP3638226A4 true EP3638226A4 (de) 2021-04-07

Family

ID=64659462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18817304.1A Pending EP3638226A4 (de) 2017-06-15 2018-06-13 Potenzial von garcinol gegen adipositas

Country Status (8)

Country Link
EP (1) EP3638226A4 (de)
JP (3) JP2020523373A (de)
KR (1) KR102289324B1 (de)
AU (1) AU2018284354A1 (de)
BR (1) BR112019026824A2 (de)
CA (1) CA3066446A1 (de)
MX (1) MX2019014841A (de)
WO (1) WO2018231923A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102136335B1 (ko) * 2020-03-24 2020-07-22 (주)메디톡스 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도
KR102363088B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 당뇨병 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 당뇨병 예방 또는 치료제 스크리닝 방법
KR102363098B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 신질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 신질환 예방 또는 치료제 스크리닝 방법
KR102191487B1 (ko) * 2020-06-19 2020-12-15 (주)메디톡스 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도
KR102363092B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 비만 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 비만 예방 또는 치료제 스크리닝 방법
KR102363094B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 간질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 간질환 예방 또는 치료제 스크리닝 방법
KR102331485B1 (ko) 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN114605242A (zh) * 2022-04-11 2022-06-10 澳门大学 间苯三酚类化合物的制备方法与药物、保健产品和食品
CN114847475B (zh) * 2022-07-05 2022-11-29 广东金骏康生物技术有限公司 一种促进akk菌生长的发酵槐米粉的应用
CN115637242A (zh) * 2022-10-20 2023-01-24 中南大学 微生物复合菌剂及其制备方法和赤泥原位生物脱碱的方法
CN116903760A (zh) * 2023-05-25 2023-10-20 浙江大学 木耳多糖及其制备方法和抑制肥胖的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063861B2 (en) * 2000-08-17 2006-06-20 Sabinsa Corporation Bioavailable composition of natural and synthetic HCA

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000044468A (ja) * 1998-07-29 2000-02-15 Kikkoman Corp リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤
JP5980228B2 (ja) * 2010-12-30 2016-08-31 ムハンメド マジード ガルシノールの肝臓保護活性
US8329743B2 (en) * 2011-01-10 2012-12-11 Sami Labs Limited Compositions and its use in treating obesity or inducing weight loss
CA3092318A1 (en) * 2012-09-20 2014-03-27 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
WO2015049553A1 (en) * 2013-10-03 2015-04-09 Delhi Institute Of Pharmaceutical Sciences And Research Effect of garcinol in delaying the progression of diabetic nephropathy
EP3130236B1 (de) * 2014-03-24 2020-08-05 Daicel Corporation Ernährungszusammensetzung
CA2934156A1 (en) * 2015-11-10 2017-05-10 Muhammed Majeed Use of forskolin in the treatment of obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063861B2 (en) * 2000-08-17 2006-06-20 Sabinsa Corporation Bioavailable composition of natural and synthetic HCA

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIN-LIN HSU ET AL: "Inhibitory effects of garcinol and pterostilbene on cell proliferation and adipogenesis in 3T3-L1 cells", FOOD & FUNCTION, vol. 3, no. 1, 18 November 2011 (2011-11-18), GB, pages 49 - 57, XP055234362, ISSN: 2042-6496, DOI: 10.1039/C1FO10209E *
HEO JAEYOUNG ET AL: "Gut microbiota Modulated by Probiotics and Garcinia cambogia Extract Correlate with Weight Gain and Adipocyte Sizes in High Fat-Fed Mice", SCIENTIFIC REPORTS, vol. 6, no. 1, 23 September 2016 (2016-09-23), XP055776502, Retrieved from the Internet <URL:http://www.nature.com/articles/srep33566> DOI: 10.1038/srep33566 *
WEI-LUN HUNG ET AL: "Protective effects of garcinol on dimethylnitrosamine-induced liver fibrosis in rats", FOOD & FUNCTION, vol. 5, no. 11, 1 January 2014 (2014-01-01), GB, pages 2883 - 2891, XP055755272, ISSN: 2042-6496, DOI: 10.1039/C4FO00342J *

Also Published As

Publication number Publication date
KR102289324B1 (ko) 2021-08-12
MX2019014841A (es) 2020-02-17
AU2018284354A1 (en) 2020-01-16
JP2021185156A (ja) 2021-12-09
KR20200012978A (ko) 2020-02-05
CA3066446A1 (en) 2018-12-20
WO2018231923A1 (en) 2018-12-20
JP2022097521A (ja) 2022-06-30
JP2020523373A (ja) 2020-08-06
EP3638226A1 (de) 2020-04-22
BR112019026824A2 (pt) 2020-06-30

Similar Documents

Publication Publication Date Title
EP3638226A4 (de) Potenzial von garcinol gegen adipositas
EP3515298A4 (de) Messung von ödemen
EP3623957A4 (de) Erzeugung einer kopie eines interessenpunkts
EP3360534A4 (de) Sprühbares sonnenschutzkosmetikum
EP3479817A4 (de) Kosmetikum
EP3353995A4 (de) Hierarchien von internet-der-dinge-vorrichtungen
EP3638808A4 (de) Detektion gezielter sequenzregionen
EP3500286A4 (de) N-carboxyanhydrid-basierte skalensynthese von elamipretid
EP3603615A4 (de) Kosmetikum
EP3607327A4 (de) Testkassette zur verwendung am versorgungsort
EP3403642A4 (de) Kosmetikum
EP3673894A4 (de) Kosmetikum
EP3310794A4 (de) Synthese und applikation von mikroblasenbildenden verbindungen
EP3573650A4 (de) Diagnose von sklerodermie
EP3400516A4 (de) Kontextbasierte anwendungsnavigation
EP3473237A4 (de) Lippenkosmetikartikel
EP3320901A4 (de) Anwendung von dimethylamino-micheliolid
EP3636249A4 (de) Kosmetikum
EP3721889A4 (de) Verwendung von butterpyribacter intestini
EP3520789A4 (de) Neue verwendung von exanox
EP3468578A4 (de) Verwendungen von il-41
EP3456311A4 (de) Kosmetikum
EP3482750A4 (de) Neuartige verwendung eines sesquiterpenderivats
EP3703702A4 (de) Modulatoren der enac-expression
EP3714863A4 (de) Kosmetikum

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031352000

Ipc: A61K0031122000

A4 Supplementary search report drawn up and despatched

Effective date: 20210304

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/06 20060101ALI20210226BHEP

Ipc: A61P 1/00 20060101ALI20210226BHEP

Ipc: A61P 3/04 20060101ALI20210226BHEP

Ipc: A61K 31/122 20060101AFI20210226BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SAMI-SABINSA GROUP LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230509